NRG‐GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer

RT @JournalCancer: New | The combination of cediranib and olaparib demonstrated modest clinical efficacy; however, the primary end point of…

RT @JournalCancer: New | The combination of cediranib and olaparib demonstrated modest clinical efficacy; however, the primary end point of…

New | The combination of cediranib and olaparib demonstrated modest clinical efficacy; however, the primary end point of the study was not met. The combination was safe without unexpected toxicity. https://t.co/NPm7NOgvIX @OncoAlert https://t.co/ccZV5…